Log in

NASDAQ:VTGNVistagen Therapeutics Stock Price, Forecast & News

$0.49
-0.03 (-5.77 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.47
Now: $0.49
$0.53
50-Day Range
$0.43
MA: $0.50
$0.61
52-Week Range
$0.29
Now: $0.49
$1.49
Volume725,100 shs
Average Volume625,512 shs
Market Capitalization$27.33 million
P/E RatioN/A
Dividend YieldN/A
Beta0.33
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform to discover, rescue, develop, and commercialize new chemical entities (NCEs) for CNS and other diseases; and regenerative medicine involving hPSC-derived blood, cartilage, heart, and liver cells. In addition, the company develops CardioSafe 3D, an in vitro cardiac bioassay system for predicting human heart toxicity of drug rescue NCEs. VistaGen Therapeutics, Inc. has licensing, sublicensing, and collaboration agreements with BlueRock Therapeutics, LP; U.S. National Institutes of Health; Cato Research Ltd.; and University Health Network. The company was founded in 1998 and is headquartered in South San Francisco, California.
Read More
Vistagen Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.2Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.21 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VTGN
CUSIPN/A
Phone650-577-3600

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.12) per share

Profitability

Net Income$-20,770,000.00

Miscellaneous

Employees9
Market Cap$27.33 million
Next Earnings Date8/21/2020 (Estimated)
OptionableNot Optionable

Receive VTGN News and Ratings via Email

Sign-up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter.

Vistagen Therapeutics (NASDAQ:VTGN) Frequently Asked Questions

How has Vistagen Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Vistagen Therapeutics' stock was trading at $0.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, VTGN stock has decreased by 2.0% and is now trading at $0.49. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Vistagen Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vistagen Therapeutics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Vistagen Therapeutics.

When is Vistagen Therapeutics' next earnings date?

Vistagen Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 21st 2020. View our earnings forecast for Vistagen Therapeutics.

How were Vistagen Therapeutics' earnings last quarter?

Vistagen Therapeutics Inc (NASDAQ:VTGN) announced its quarterly earnings data on Monday, June, 29th. The company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.01. View Vistagen Therapeutics' earnings history.

What price target have analysts set for VTGN?

3 Wall Street analysts have issued 1-year target prices for Vistagen Therapeutics' shares. Their forecasts range from $0.70 to $1.00. On average, they expect Vistagen Therapeutics' share price to reach $0.85 in the next twelve months. This suggests a possible upside of 73.5% from the stock's current price. View analysts' price targets for Vistagen Therapeutics.

What are Wall Street analysts saying about Vistagen Therapeutics stock?

Here are some recent quotes from research analysts about Vistagen Therapeutics stock:
  • 1. According to Zacks Investment Research, "VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder. VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California. " (4/25/2020)
  • 2. Chardan Capital analysts commented, "We transfer coverage of VTGN to better align coverage with current focus areas of analysts. We downgrade to $0.70 price target. We believe that VistaGen Therapeutics now faces an uphill battle after a setback in AV-101 development, one that to us will not be aided by recent pipeline acquisitions. VistaGen announced the NIMH-sponsored phase II trial (NCT02484456) of AV-101 in treatment resistant depression (TRD) missed its primary endpoint of change from baseline on the Scale (HDRS). 19-patient study showed no separation of AV-101 from placebo. The NIMH trial evaluated AV-101 as a monotherapy, whereas VistaGen is positioning AV-101 as an adjunct therapy. However, to us a clinical trial failure does not bode well for the success for AV-101." (7/22/2019)

Has Vistagen Therapeutics been receiving favorable news coverage?

News articles about VTGN stock have trended somewhat negative recently, according to InfoTrie. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Vistagen Therapeutics earned a news sentiment score of -1.8 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news about Vistagen Therapeutics.

Who are some of Vistagen Therapeutics' key competitors?

What other stocks do shareholders of Vistagen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vistagen Therapeutics investors own include Highpower International (HPJ), AK Steel (AKS), Advaxis (ADXS), Rite Aid (RAD), Crispr Therapeutics (CRSP), Matinas BioPharma (MTNB), Lithium Americas (LAC), vTv Therapeutics (VTVT), Sorrento Therapeutics (SRNE) and Yamana Gold (AUY).

Who are Vistagen Therapeutics' key executives?

Vistagen Therapeutics' management team includes the following people:
  • Mr. Shawn K. Singh, CEO & Director (Age 56)
  • Dr. H. Ralph Snodgrass, Founder, Pres, Chief Scientific Officer & Director (Age 69)
  • Mr. Jerrold D. Dotson, CFO, VP & Sec. (Age 66)
  • Mr. Mark Adrian McPartland, VP of Corp. Devel. (Age 53)
  • Dr. Mark A. Smith, Chief Medical Officer (Age 64)

What is Vistagen Therapeutics' stock symbol?

Vistagen Therapeutics trades on the NASDAQ under the ticker symbol "VTGN."

How do I buy shares of Vistagen Therapeutics?

Shares of VTGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Vistagen Therapeutics' stock price today?

One share of VTGN stock can currently be purchased for approximately $0.49.

How big of a company is Vistagen Therapeutics?

Vistagen Therapeutics has a market capitalization of $27.33 million. The company earns $-20,770,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Vistagen Therapeutics employs 9 workers across the globe.

What is Vistagen Therapeutics' official website?

The official website for Vistagen Therapeutics is www.vistagen.com.

How can I contact Vistagen Therapeutics?

Vistagen Therapeutics' mailing address is 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-577-3600 or via email at [email protected]

This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.